Tvaster Genkalp Secures $1.25M Series A to Advance Revolutionary Hepatocellular Carcinoma Screening with Episcreen™ Liver

Tvaster Genkalp is thrilled to announce a significant funding milestone, having successfully raised $1,250,000 to further accelerate its mission in transforming cancer diagnostics. Established in May 2021, this pioneering Molecular Diagnostics company specializes in Liquid Biopsy, offering innovative blood-based cancer diagnostic solutions. With its cutting-edge approach, Tvaster Genkalp has developed the groundbreaking Episcreen™ Liver screening test for Hepatocellular carcinoma (HCC), representing a major leap forward in the early detection of liver cancer. This revolutionary test has been rigorously validated through a comprehensive clinical study that involved over 750 patients, demonstrating an impressive sensitivity of 90%—a striking improvement over the current blood-based biomarker, AFP, which has only a 50% sensitivity. Moreover, Episcreen™ Liver was able to detect 92% of the HCC cases missed by AFP, potentially providing a life-saving solution for countless individuals at risk. The recently raised funds will be strategically invested in expanding the company’s research and development capabilities, while also broadening the clinical adoption of Episcreen™ Liver. Tvaster Genkalp is committed to enhancing early cancer detection and improving patient outcomes through its state-of-the-art diagnostic solutions, and this new round of funding is a testament to the market’s growing confidence in their technology. By catalyzing further innovation, the infusion of capital will help streamline production, extend clinical trials, and support regulatory approvals globally. Tvaster Genkalp’s dedication to quality and patient care remains at the forefront as it continues to push the boundaries of cancer diagnostics, setting a new standard for early detection and potentially saving many lives in the process.